ArticleProstate international2026
Risk stratification for repeat prostate biopsy: PI-RADS 3 lesions and the differential role of PSA density.
Article in Prostate international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Value of PSA density in PI-RADS 3 lesions: a single-center retrospective observational study.International urology and nephrology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: PI-RADS 3 lesions represent a diagnostic challenge in repeat prostate biopsy. We investigated whether PI-RADS 3 independently predicts negative biopsy outcomes and how PSA density (PSAD) modifies cancer detection across PI-RADS categories. Materials and methods: We retrospectively analyzed 684 patients who underwent repeat MRI-guided prostate biopsy between 2015 and 2022. PI-RADS scores, clinicopathologic variables, biopsy Gleason Scores, and radical prostatectomy findings were assessed. Univariate and multivariate logistic regression identified predictors of positive biopsy. Subgroup analysis examined detection rates stratified by PI-RADS and PSAD. Results: Overall, 238 patients (34.8 %) had positive biopsies. PI-RADS 3 was identified in 210 patients (30.7 %) and PI-RADS 4-5 in 274 (40.1 %). Cancer detection differed significantly: 19.0 % for PI-RADS 3 versus 51.8 % for PI-RADS 4-5 ( Conclusion: PI-RADS 3 lesions independently predict negative biopsy in repeat MRI-guided prostate biopsy. PSAD demonstrates differential predictive utility across PI-RADS categories. Risk-stratified management incorporating imaging and clinical biomarkers may optimize decision-making while minimizing unnecessary procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.